Portal de Periódicos da CAPES

The Efficacy of Intravesical Tice Strain Bacillus Calmette-Guerin in the Treatment of Interstitial Cystitis: A Double-Blind, Prospective, Placebo Controlled Trial

1997; Lippincott Williams & Wilkins; Volume: 157; Issue: 6 Linguagem: Inglês

10.1016/s0022-5347(01)64682-2

1527-3792

Kenneth M. Peters, Ananias C. Diokno, Bruce W. Steinert, Manuel Yuhico, Brent Mitchell, Sherrie Krohta, Beverly Gillette, Jose A. Gonzalez,

Urinary Tract Infections Management

No AccessJournal of UrologyClinical Urology: Original Article1 Jun 1997The Efficacy of Intravesical Tice Strain Bacillus Calmette-Guerin in the Treatment of Interstitial Cystitis: A Double-Blind, Prospective, Placebo Controlled Trial Kenneth Peters, Ananias Diokno, Bruce Steinert, Manuel Yuhico, Brent Mitchell, Sherrie Krohta, Beverly Gillette, and Jose Gonzalez Kenneth PetersKenneth Peters , Ananias DioknoAnanias Diokno , Bruce SteinertBruce Steinert , Manuel YuhicoManuel Yuhico , Brent MitchellBrent Mitchell , Sherrie KrohtaSherrie Krohta , Beverly GilletteBeverly Gillette , and Jose GonzalezJose Gonzalez View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)64682-2AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Interstitial cystitis is a debilitating bladder disease of unknown etiology with no cure. A recent report suggested that bacillus Calmette-Guerin (BCG) may be effective in the treatment of interstitial cystitis. A randomized, prospective, double-blind, placebo controlled trial to evaluate the safety and efficacy of intravesical BCG in treating interstitial cystitis was done. Materials and Methods: Patients meeting the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases criteria for interstitial cystitis received 6 weekly instillations of Tice strain BCG or placebo. Periodic questionnaires, voiding diaries and cystometrograms were obtained. A total of 30 evaluable subjects was enrolled in the study with a mean followup of 8 months (range 6 to 13). Based on an exit questionnaire a responder was defined as one who rated the interstitial cystitis symptoms as moderately improved or better. Results: A 60% BCG response rate was noted, compared to a 27% placebo response rate. Minimum voided volume and quality of life improved in the BCG group compared to placebo. Adverse events were similar in each group, mostly irritative in nature, and no significant systemic events were noted. Conclusions: Intravesical Tice strain BCG appears to be safe and efficacious in the treatment of interstitial cystitis. Additional studies must be performed to confirm the results of this pilot study. References 1 : A rare type of bladder ulcer in women: report of cases. Boston Med. Surg. J.1915; 172: 660. Google Scholar 2 : Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases workshop on interstitial cystitis, National Institutes of Health, Bethesda, Maryland, August 28-29, 1987. J. Urol.1988; 140: 203. Abstract, Google Scholar 3 : Bacillus Calmette-Guerin immunotherapy for refractory interstitial cystitis. Urology1994; 43: 121. Google Scholar 4 : The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care1992; 30: 473. Google Scholar 5 : Measurement of symptoms of interstitial cystitis. A pilot study. Urol. Clin. N. Amer.1994; 21: 67. Google Scholar 6 : A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J. Urol.1993; 150: 845. Link, Google Scholar 7 : Self-care regimens for patients with interstitial cystitis. Urol. Clin. N. Amer.1994; 21: 121. Google Scholar 8 : Evidence for urothelial cell activation in interstitial cystitis. J. Urol.1993; 149: 470. Link, Google Scholar 9 : Abnormal urothelial HLA-DR expression in interstitial cystitis. Clin. Exp. Immunol.1992; 87: 450. Google Scholar 10 : Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet1983; 2: 1115. Google Scholar 11 : Class II antigen (HLA-DR) expression by intestinal epithelial cells in inflammatory diseases of colon. J. Clin. Path.1987; 40: 312. Google Scholar 12 : Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J. Exp. Med.1986; 164: 1013. Google Scholar 13 : HLA-DR expression by high grade superficial bladder cancer treated with BCG. Brit. J. Urol.1989; 63: 264. Google Scholar From the Department of Urology, William Beaumont Hospital, Royal Oak, Michigan.© 1997 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byPropert K, Mayer R, Nickel J, Payne C, Peters K, Teal V, Burks D, Kusek J, Nyberg L and Foster H (2007) Did Patients With Interstitial Cystitis Who Failed to Respond to Initial Treatment With Bacillus Calmette-Guerin or Placebo in a Randomized Clinical Trial Benefit From a Second Course of Open Label Bacillus Calmette-Guerin?Journal of Urology, VOL. 178, NO. 3, (886-890), Online publication date: 1-Sep-2007.MAYER R, PROPERT K, PETERS K, PAYNE C, ZHANG Y, BURKS D, CULKIN D, DIOKNO A, HANNO P, LANDIS J, MADIGAN R, MESSING E, NICKEL J, SANT G, WARREN J, WEIN A, KUSEK J, NYBERG L and FOSTER H (2018) A RANDOMIZED CONTROLLED TRIAL OF INTRAVESICAL BACILLUS CALMETTE-GUERIN FOR TREATMENT REFRACTORY INTERSTITIAL CYSTITISJournal of Urology, VOL. 173, NO. 4, (1186-1191), Online publication date: 1-Apr-2005.PARKER C, STEELE S, RAGHAVAN R, EVANS G, CRANNEY A, ROBB S and NICKEL J (2018) HYPERSENSITIVITY REACTION ASSOCIATED WITH INTRAVESICAL BACILLUS CALMETTE-GUERIN FOR INTERSTITIAL CYSTITISJournal of Urology, VOL. 172, NO. 2, (537-537), Online publication date: 1-Aug-2004.PEEKER R, HAGHSHENO M, HOLMÄNG S and FALL M (2018) INTRAVESICAL BACILLUS CALMETTE-GUERIN AND DIMETHYL SULFOXIDE FOR TREATMENT OF CLASSIC AND NONULCER INTERSTITIAL CYSTITIS:: A PROSPECTIVE, RANDOMIZED DOUBLE-BLIND STUDYJournal of Urology, VOL. 164, NO. 6, (1912-1916), Online publication date: 1-Dec-2000.BARBALIAS G, LIATSIKOS E, ATHANASOPOULOS A and NIKIFORIDIS G (2018) INTERSTITIAL CYSTITIS: BLADDER TRAINING WITH INTRAVESICAL OXYBUTYNINJournal of Urology, VOL. 163, NO. 6, (1818-1822), Online publication date: 1-Jun-2000.WARREN J, HORNE L, HEBEL J, MARVEL R, KEAY S and CHAI T (2018) PILOT STUDY OF SEQUENTIAL ORAL ANTIBIOTICS FOR THE TREATMENT OF INTERSTITIAL CYSTITISJournal of Urology, VOL. 163, NO. 6, (1685-1688), Online publication date: 1-Jun-2000.KORTING G, SMITH S, WHEELER M, WEISS R and FOSTER H (2018) A RANDOMIZED DOUBLE-BLIND TRIAL OF ORAL L-ARGININE FOR TREATMENT OF INTERSTITIAL CYSTITISJournal of Urology, VOL. 161, NO. 2, (558-565), Online publication date: 1-Feb-1999.PETERS K, DIOKNO A, STEINERT B and GONZALEZ J (2018) THE EFFICACY OF INTRAVESICAL BACILLUS CALMETTE-GUERIN IN THE TREATMENT OF INTERSTITIAL CYSTITIS: LONG-TERM FOLLOWUPJournal of Urology, VOL. 159, NO. 5, (1483-1487), Online publication date: 1-May-1998.GOIN J, OLALEYE D, PETERS K, STEINERT B, HABICHT K and WYNANT G (2018) PSYCHOMETRIC ANALYSIS OF THE UNIVERSITY OF WISCONSIN INTERSTITIAL CYSTITIS SCALE: IMPLICATIONS FOR USE IN RANDOMIZED CLINICAL TRIALSJournal of Urology, VOL. 159, NO. 3, (1085-1090), Online publication date: 1-Mar-1998. Volume 157Issue 6June 1997Page: 2090-2094 Advertisement Copyright & Permissions© 1997 by American Urological Association, Inc.MetricsAuthor Information Kenneth Peters More articles by this author Ananias Diokno More articles by this author Bruce Steinert More articles by this author Manuel Yuhico More articles by this author Brent Mitchell More articles by this author Sherrie Krohta More articles by this author Beverly Gillette More articles by this author Jose Gonzalez More articles by this author Expand All Advertisement PDF downloadLoading ...